Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: Potential role in further increasing dose-intensity

Leukemia and Lymphoma

Volumn 27, Issue 3-4, 1997, Pages 343-349

  O'Flaherty, Elizabeth ^a   Cebon, Jonathon ^b   Grigg, Andrew P ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

G CSF; High dose chemotherapy; NHL; Progenitors

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ARTICLE; BLOOD STORAGE; BURST FORMING UNIT E; CELL VIABILITY; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030856909     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709059689     Document Type: Article

References (15)

1. Gurney, H., Dudwell, D., Thatcher. N. and Tattersall, M. (1993). Escalating drug delivery in cancer chemotherapy: A review of concepts and practice-part 2. Annals of Oncology, 4, 103-115.
2. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D., James, R., Wilkinson, P., Kane, K., Bentley, J. and Crowther, D. (1992). Granulocyte colony-stimulating factor to prevent dose limiting neutropenia in non-Hodgkin's lymphoma: a randomised controlled trial. Blood, 80, 1430-1436.
3. Duhrsen, U., Villeval, J. L., Boyd. J., Kannourakis, G., Morslyn, G. and Metcalf. D. (1988). Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood, 72, 2074-2081.
4. Lickliter, J., Begley, C. G., Boyd, A. and Grigg, A. P. (1994). Combined chemotherapy and granulocyte colony-stimulating factor mobilise large numbers of peripheral blood progenitor cells in pretreated patients, Leukemia and Lymphoma. 15. 91-97.
5. Pettengell, R., Wall, P. J., Thatcher, N., Dexter, M. and Testa, N. G. (1995). Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. Journal of Clinical Oncology, 13. 148-156.
6. Ossenkoppele. G. J., Schuurhuis, G. J., Jonkhoff, A. R., Drager, A. M., Westra, G., Oberink, J. W., Lcgdeur. M. C. J. C., de Kreuk. A. M., Zweegman. S. and Huijgens, P. C. (1996). GCSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a BEAM-like regimen in had risk lymphoma. Bone Marrow Transplantation, 18, 427-431.
7. Grigg, A. P., Wolf, M., Levi, J., Bartlett, J. and Green, M. (1996). Escalated dose epirubicin-cyclophosphamide with filgrastim for patients with aggressive non-Hodgkin's lymphoma. Proc ASCO, 15, 411, abstract no. 1255.
8. Goss, G., Szer, J. and Grigg, A. P. (1996). Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells. Australian and New Zealand Journal of Medicine, 26, 411-413.
9. Sheridan, W., Begley. C. G., To, L. B., Grigg, A. P., Szer, J., Mither, D., Green, M. D., Rowlings, P. A., McGrath, K. M., Cebon, J., Dyson, P., Watson. D., Bayly, J., de Luca, E., Tomila, D., Hoffman, E., Morstyn, G., Juttner, C. A., Fox, R. M. (1994). Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Transplantation, 14, 105-111.
10. Pettengell, R., Woll, P. J., O'Connor. D. A., Dexter, T. M. and Testa, N. G. (1994). Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplantation, 14, 703-709.
11. Stiff, P. J., Koester, A. R., Weidner, M. K., Dvorak, K. and Fisher, R. (1987). Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethyl-sulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood, 70, 974-978.
12. Shipp, M. A., Neuberg, D., Janicek, M., Canellos, G. P., Shulman, L. N. (1995). High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose finding pilot study. Journal of Clinical Oncology, 13(12), 2916-2923.
13. Haas, R., Mohle, R., Fruhauf, S., Goldschmidt, H., Witt, B., Flentje, M., Wannenmacher, M. and Hunstein, W. (1994). Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood, 83. 3387-3794.
14. Pettengell, R., Testa, N. G., Swindell, R., Crowther. D. and Dexter, M. (1993). Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood, 82, 2239-2248.
15. Grigg, A. P., Roberts, A. W., Raunow. H., Houghton, S., Layton, J., Boyd. A. W., McGrath, K. M. and Maher, D. (1995). Optimising dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 86, 4437-4445.